GLP1R and diabetes mellitus: A pooled meta-analysis of the ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6, and AMPLITUDE-O trials conducted by Lancet Diabetes Endocrinol 2021 revealed that GLP-1 RAs resulted in a 14% relative risk reduction for three-point MACES compared with placebos (hazard ratio: 0.86, 95% CI: 0.80–0.93; p < 0.0001).